Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations

NCT05904730 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Ovarian Cancer
Breast Neoplasms
Ovarian Neoplasms
BRCA Mutation
HER2-positive Breast Cancer
HER2-negative Breast Cancer
HER-2 Protein Overexpression

Interventions

DRUG: Axitinib

Sponsor

Lynkcell Europe